It’s well-established that smoking increases risk for developing MS. For our preliminary metabolomics work we focused solely on non-smoking individuals to keep that factor from complicating our data analysis. Interestingly,...
MS is an autoimmune disease, the most common neurological disease of young adults. It damages neurons in the brain and spinal cord (the central nervous system).
MS affects 400,000 individuals in the U.S and 2.5 million worldwide.
Although substantial advances have been made in the development of therapeutic treatments, the drugs currently available to MS patients do not significantly alter the long-term prognosis of the disease. Better markers that represent the biological activity of the disease process and the response to therapy are desperately needed, as are novel therapies that halt disease progression rather than just modify it.